Background
Methods
Data sources, search strategy, and eligibility criteria
Data extraction
Data synthesis and analysis
Results
Study identification and selection
Characteristics of included studies
Study name (year) | FU (months) | SBPTa
study | P-h/sa of RCTs analysis | N participants | Antihypertensive | Age (SD) | Women (%) | Hypertension (%) | Diabetes (%) | Smoking (%) | Previous coronary disease (%) | Previous cerebrovascular disease (%) | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Intervention | Control | Intervention | Control | |||||||||||
140 to < 150 mmHg | ||||||||||||||
HOT [14] (2000) | 45 | No | Yes | nd | nd | Thiazide, BB, CCB or ACEi | Thiazide, BB, CCB or ACEi | 70.6 (3.9) | 54 | 100 | 10 | 11 | 13 | |
130 to < 140 versus ≥ 140 mmHg | ||||||||||||||
EWPHE [30] (1989) | 9 | Yes | Yes | 120 | 126 | thiazide + triamterene | thiazide + triamterene | 71.4 (6.9) | 70 | 100 | nd | 19 | 35 | |
JATOS [10] (2008) | 24 | Yes | No | 2212 | 2206 | CCB | CCB | 73.6 (5.2) | 61 | 100 | 11 | 13 | 3 | 4 |
VALISH [11] (2010) | 33 | Yes | No | 1545 | 1534 | ARB | ARB | 76.1 (4.1) | 62 | 100 | 13 | 19 | 5 | 6 |
ADVANCE [28] (2010) 65–74 yo | 51 | No | Yes | 2845 | 2760 | Thiazide + ACEi | Placebo + usual antiHTN drug treatmentc
| 68 (nd) | 42 | 61 | 100 | 10 | 11 | 8 |
ADVANCE [28] (2010) ≥ 75 yo | 51 | No | Yes | 490 | 518 | Thiazide + ACEi | Placebo + usual antiHTN drug treatmentc
| 77 (nd) | 40 | 67 | 100 | 6 | 16 | 12 |
FEVER [21] (2011) | 40 | Yes | Yes | 1631 | 1548 | Thiazide + CCB | Thiazide + Placebo | > 65 | 61b
| 100 | 12b
| 29b
| 2b
| 10b
|
Wei et al. [24] (2013) | 48 | Yes | No | 363 | 361 | Thiazide, ACEi, BB or CCB | Thiazide, ACEi, BB or CCB | 76.5 (4.5) | 33 | 100 | 23 | 24 | nd | 6 |
INVEST [27] (2014) | 24 | Yes | Yes | 4787 | 1747 | CCB/ACEi or BB/thiazide | CCB/ACEi or BB/thiazide | 70.7 (7.3) | 55 | 100 | 29 | 42 | 100 | 8 |
< 130 versus ≥ 130 mmHg | ||||||||||||||
LIFE [22] (2012) | 55 | Yes | Yes | 5704e
| ARB or BB | ARB or BB | ≥ 65 | 54b
| 100 | 13b
| 16b
| 16b
| 4b
| |
SPS3 [12] (2015) | 42 | Yes | Yes | 248 | 246 | Any | Any | 79.9 (3.8) | 45 | 77 | 27 | 5 | 10 | 100 |
37 | Yes | Nod
| 1317 | 1319 | Any | Any | 79.8 (4) | 38 | nd | 0 | 13b
| 24,5 | 0 |
Study name (year) | Baseline BP (SD, mmHg) | Final SBP (SD, mmHg) | Final DBP (SD, mmHg) | Outcome (HR or RR and CI 95%) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
SBP | DBP | Intervention | Control | Intervention | Control | Stroke | AMI | HF | CV mortality | All-cause mortality | |
140 to < 150 mmHg | |||||||||||
HOT [14] (2000) | 175 (15) | 105.3 (3.9) | 143 (15) | 147 (16) | 83 (8) | 80 (7) | 0.85 (nd)b
| 0.72 (nd)b
| nd | 1.05 (nd)b
| 0.98 (nd)b
|
130 to < 140 versus ≥ 140 mmHg | |||||||||||
EWPHE [30] (1989) | 182 (nd) | 101 (nd) | 134 (nd) | 152 (nd) | 84 (nd) | 88 (nd) | nd | nd | nd | 2.49 (1.34–4.57) | 2.00 (1.28–3.09) |
JATOS [10] (2008) | 171.5 (9.7) | 89.1 (9.5) | 135.9 (11.7) | 145.6 (11.1) | 74.8 (9.1) | 78.1 (8.9) | 1.08 (0.74–1.56) | 0.99 (0.33–2.80) | 1.16 (0.41–3.12) | 1.28 (0.48–3.38) | 1.26 (0.85–1.85) |
VALISH [11] (2010) | 165.5 (7.9) | 81.4 (6.7) | 136.6 (13.3) | 142 (12.5) | 74.8 (8.8) | 76.5 (8.9) | 0.68 (0.36–1.29) | 1.23 (0.33–4.56) | nd | 0.97 (0.42–2.25) | 0.78 (0.46–1.33) |
ADVANCE [28] (2010) 65–74 yo | 146 (22) | 80 (11) | 135 (10.6) | 140.5 (15.7) | 77.8 (10.6) | 74 (5.1) | nd | nd | nd | 0.86 (0.67–1.10) | 0.84 (0.70–1.00) |
ADVANCE [28] (2010) ≥ 75 yo | 151 (22) | 78 (11) | 137 (11) | 143.9 (18.2) | 75.7 (8.8) | 72(6.8) | nd | nd | nd | 0.65 (0.44–0.98) | 0.90 (0.68–1.19) |
FEVER [21] (2011) | 154.3 (12)a
| 92.5 (9.6) | 139.7 (nd) | 145.5 (nd) | 81.2 (nd) | 83.6 (nd) | 0.56 (0.41–0.74) | nd | nd | 0.51 (0.33–0.81) | 0.64 (0.45–0.91) |
Wei et al. [24] (2013) | 159.54 (16.4) | 84.2 (9.5) | 135.7 (9) | 149.7 (11) | 76.2 (6.1) | 82.1 (7.5) | 0.57 (0.34–0.94) | 1.00 (0.42–2.33) | 0.37 (0.15–0.91) | 0.49 (0.31–0.77) | 0.58 (0.43–0.78) |
INVEST [27] (2014) | 165.4 (13.8) | 90.2 (11.1) | 135.8 (nd) | 145 (nd) | nd | nd | 0.52 (0.35–0.79) | 0.83 (0.62–1.11) | 0.93 (0.63–1.36)b
| 0.74 (0.56–0.99) | 0.97 (0.80–1.16) |
< 130 versus ≥ 130 mmHg | |||||||||||
LIFE [22] (2012) | 176.3 (13.2) a
| 98 (9) a
| 120 (nd) | 151 (nd) | nd | nd | nd | nd | nd | nd | 1.28 (1.0–1.64) |
SPS3 [12] (2015) | 144.4 (20) | nd | 125.2 (15.8) | 137.1 (14.6) | nd | nd | 1.01 (0.59–1.73)b
| 0.77 (0.23–2.52)b
| nd | 0.39 (0.16–0.92) | 0.83 (0.53–1.29)b
|
SPRINT [13] (2016) | 141.6 (15.7) | 71.2 (11.0) | 123.4 (8.3) | 134.8 (8.3) | 62.0 (5.5) | 67.2 (6.4) | 0.72 (0.43–1.21) | 0.69 (0.45–1.05) | 0.62 (0.40–0.95) | 0.60 (0.33–1.09) | 0.67 (0.49–0.91) |